HANMI SCIENCE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33,500 KRW | +0.60% |
|
+4.69% | -14.54% |
| Sales 2022 | 1,046B 760M 1.04B | Sales 2023 | 1,248B 907M 1.24B | Capitalization | 2,665B 1.94B 2.65B |
|---|---|---|---|---|---|
| Net income 2022 | 69.21B 50.32M 68.73M | Net income 2023 | 115B 83.69M 114M | EV / Sales 2022 | 2.28 x |
| Net Debt 2022 | 180B 131M 179M | Net Debt 2023 | 179B 130M 178M | EV / Sales 2023 | 2.28 x |
| P/E ratio 2022 |
32.1
x | P/E ratio 2023 |
23.1
x | Employees | 403 |
| Yield 2022 |
0.62% | Yield 2023 |
0.51% | Free-Float | 28.5% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.60% | ||
| 1 week | +4.69% | ||
| Current month | -12.53% | ||
| 1 month | -17.59% | ||
| 3 months | -23.25% | ||
| 6 months | +8.06% | ||
| Current year | -14.54% |
1 week
32 250.00
33 800.00
1 month
31 250.0042 550.00
Current year
31 250.0056 200.00
1 year
29 850.0056 200.00
3 years
28 480.3990 061.51
5 years
17 857.0192 848.90
10 years
10 111.86177 364.28
| Managers | Title | Age | Since |
|---|---|---|---|
Young-Sook Song
CEO | Chief Executive Officer | 76 | - |
Jong-Hoon Lim
CEO | Chief Executive Officer | 47 | 04-03 |
Ki-Ho Song
DFI | Director of Finance/CFO | 52 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jong-Yoon Lim
BRD | Director/Board Member | 51 | - |
| 49 | - | ||
Jong-Hoon Lim
CEO | Chief Executive Officer | 47 | 04-03 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.74% | 2 M€ | -14.14% | ||
| 0.01% | 4 M€ | -4.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 33,500 | +0.60% | 57,224 |
| 24-04-25 | 33,300 | -1.33% | 71,071 |
| 24-04-24 | 33,750 | +1.35% | 114,852 |
| 24-04-23 | 33,300 | +1.37% | 105,781 |
| 24-04-22 | 32,850 | +2.66% | 126,621 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
Hanmi Science Co Ltd is a Korean-based holding company principally involved in the management of subsidiaries. Through subsidiaries in Japan, Europe and Korea, the Company operates in three segments. The Pharmaceutical Products Wholesale segment mainly engages in the distribution of pharmaceutical products. The Holding Business segment mainly engages in the business of controlling subsidiaries. The Other segment mainly engage in the production and sales of pharmaceuticals, and the supply of quasi-drugs and health functional foods, beverages and functional cosmetics.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -14.54% | 1.65B | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- A008930 Stock
